Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) Invested Capital (2016 - 2025)

Historic Invested Capital for Organogenesis Holdings (ORGO) over the last 10 years, with Q3 2025 value amounting to $255.1 million.

  • Organogenesis Holdings' Invested Capital fell 1032.75% to $255.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $255.1 million, marking a year-over-year decrease of 1032.75%. This contributed to the annual value of $262.9 million for FY2024, which is 747.92% down from last year.
  • Organogenesis Holdings' Invested Capital amounted to $255.1 million in Q3 2025, which was down 1032.75% from $233.2 million recorded in Q2 2025.
  • Organogenesis Holdings' Invested Capital's 5-year high stood at $315.4 million during Q4 2021, with a 5-year trough of $227.3 million in Q1 2021.
  • In the last 5 years, Organogenesis Holdings' Invested Capital had a median value of $268.7 million in 2023 and averaged $268.6 million.
  • In the last 5 years, Organogenesis Holdings' Invested Capital soared by 8424.61% in 2021 and then tumbled by 1472.8% in 2023.
  • Quarter analysis of 5 years shows Organogenesis Holdings' Invested Capital stood at $315.4 million in 2021, then dropped by 14.33% to $270.2 million in 2022, then grew by 5.16% to $284.1 million in 2023, then fell by 7.48% to $262.9 million in 2024, then fell by 2.96% to $255.1 million in 2025.
  • Its Invested Capital stands at $255.1 million for Q3 2025, versus $233.2 million for Q2 2025 and $242.9 million for Q1 2025.